GMAX R&D Team is Selected as “Leading Innovation Team”, Zhejiang Provi

The GMAX R&D Team on “Diabetes, obesity and pulmonary hypertension” is recently selected as the “Leading Innovation Team of the Zhejiang Province, 2017”.

GMAX to Present at the 78th ADA Scientific Sessions

June 22, 2018, Gmax Biopharm, a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, announced today that it will present the recent clinical progresses of its GLP-1R antibody Glutazumab ...

GMAX to Present at the PHA’s 2018 International PH Conference and Scie

June 28, 2018, Gmax Biopharm, a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, announced today that it will present the preclinical and the phase 1 clinical trial results of its ETa antibody Getagozumab ...